Ads
related to: drugs approved for prostate cancer- Doctor Discussion Guide
Use This List and Come Prepared to
Discuss Options with Your Doctor.
- Clinical Glossary
Need Help Decoding Medical Words?
Our Clinical Glossary Can Help.
- Real People, Real Stories
Visit Site to Watch Patient Videos
& Learn About Their Journey.
- Downloadable Resources
Browse Helpful Resources
for Patients and Caregivers.
- Doctor Discussion Guide
Search results
Results from the WOW.Com Content Network
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
Apalutamide was approved by the Food and Drug Administration in the United States, under the brand name Erleada, for the treatment of non-metastatic castration-resistant prostate cancer in February 2018. [8] [9] It was subsequently approved in Canada, the European Union, and Australia. [42] [6]
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
[13] [102] In men with early prostate cancer, bicalutamide monotherapy has been found to increase non-prostate cancer mortality. [26] [124] [13] The reasons for the increase in mortality with bicalutamide in these men are unknown, but possible factors could include androgen deprivation or drug-related toxicity of bicalutamide. [125] [126]
In doing so, it prevents the effects of these hormones in prostate cancer. [10] Abiraterone acetate was described in 1995, and approved for medical use in the United States and the European Union in 2011. [11] [2] It is on the World Health Organization's List of Essential Medicines. [12] It is available as a generic medication. [13]
On Friday, Johnson & Johnson's Zytiga received an expanded approval from the European Commission. The drug was previously approved for patients with metastatic castration-resistant prostate cancer ...
Ads
related to: drugs approved for prostate cancer